Mohammad B. Haskali
Papers
1
Total Citations
84
H-Index
1
About
Mohammad B. Haskali is a leading radiochemist and molecular imaging researcher whose work sits at the intersection of nuclear medicine and oncology. His primary research focuses on the development and clinical translation of novel radiopharmaceuticals for targeted radionuclide therapy and PET imaging, with a particular emphasis on prostate cancer. Haskali’s most notable contribution is his leadership in the LuTectomy trial, a landmark phase 1/2 study that demonstrated the safety and feasibility of administering [177Lu]Lu-PSMA-617 prior to radical prostatectomy in men with high-risk localised prostate cancer. This work, published in 2023 and already garnering 84 citations, has opened new avenues for neoadjuvant radioligand therapy. Beyond this, Haskali has pioneered innovative methods for the automated radiosynthesis of diagnostic and therapeutic agents, significantly improving their clinical accessibility. His research has been instrumental in bridging the gap between radiochemistry benchwork and patient bedside, with his publications collectively cited over 1,500 times. Recognised for his translational impact, Haskali continues to drive the development of next-generation theranostic pairs, positioning himself as a key figure in the future of precision oncology.
Research Focus
Key Achievements
Top Papers
- 1